Zafemy Patch
Product Images NDC 72162-2220

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Zafemy (NDC 72162-2220). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622220)

ZAFEMY (Norelgestromin and Ethinyl estradiol) transdermal system patch delivering 150/35 mcg per day. The label states each 12.5 cm² system contains 3.15 mg norelgestromin and 0.289 mg ethinyl estradiol. The package includes 3 transdermal systems, relabeled by Bryant Ranch Prepack and manufactured by Amneal Pharmaceuticals LLC. Storage and usage precautions are also provided.*

FDA Label Image

Where To Put Patch (Zafemy Norelgestromin And Ethinyl Estradiol Transd 1)

A series of four images demonstrating the application sites for ZAFEMY transdermal patches. The patches are shown applied to the upper arm, lower abdomen near the hip, buttock, and upper back near the shoulder, illustrating typical placement areas for this transdermal contraceptive patch.*

FDA Label Image

Figure 4 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 10)

Line graph showing EE (Ethinyl Estradiol) concentration (pg/mL) over time (hours) with data points for Cycle 1 Week 1, Cycle 3 Week 1, Cycle 3 Week 2, and Cycle 3 Week 3. The graph displays concentration trends during 0 to 240 hours, illustrating fluctuations and a decline after approximately 168 hours.*

FDA Label Image

Figure 5 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 11)

A line graph comparing the Norelgestromin (NGMN) concentration (ng/mL) over time (hours) for ZAFEMY applied to the buttock versus an oral contraceptive containing NGMN 250 ug and Ethinyl Estradiol 35 ug. The graph displays plasma concentration changes from 0 to 240 hours, showing different pharmacokinetic profiles for the transdermal patch and oral contraceptive, including estimated steady-state data for the oral form based on day 21.*

FDA Label Image

Figure 6 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 12)

A pharmacokinetic graph depicting Ethinyl Estradiol (EE) concentration in pg/mL over time in hours (h). It compares EE levels following application of the ZAFEMY patch to the buttock versus oral contraceptive administration of Norelgestromin 250 µg and EE 35 µg. The chart includes estimated steady-state data based on day 21 for the oral contraceptive.*

FDA Label Image

01 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 13)

A vertical arrow chart showing pregnancy rates per 100 women per year on the y-axis, labeled with fewer pregnancies at the top and more pregnancies at the bottom. Categories listed alongside the arrow are different birth control methods grouped by effectiveness, from implants and sterilization at the lowest pregnancy rates to no birth control at the highest.*

FDA Label Image

02 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 14)

A calendar-style illustration depicting a 4-week schedule for ZAFEMY transdermal patches. It shows daily boxes for weeks 1 through 3 with arrows indicating continuous patch use, and week 4 marked with 'NO PATCH' to indicate a patch-free period. Days of the week are labeled Sunday through Saturday.*

FDA Label Image

03 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 15)

A horizontal bar chart illustrating the range of blood clot cases per 10,000 woman-years among different groups: Non-CHC users who are non-pregnant, CHC users, pregnant women, and postpartum women within 12 weeks. The chart displays ranges of cases for each group along the horizontal axis labeled 'Number of Women with a Blood Clot out of 10,000 Woman-Years (WY)'.*

FDA Label Image

Figure A (Zafemy Norelgestromin And Ethinyl Estradiol Transd 16)

Illustration showing hands peeling a protective backing off a transdermal patch, demonstrating how to remove the patch from its protective packaging. The image is related to the application of a transdermal patch drug delivery system.*

FDA Label Image

Figure B (Zafemy Norelgestromin And Ethinyl Estradiol Transd 17)

Image of a hand holding a square, beige transdermal patch. This is representative of the ZAFEMY patch, which contains norelgestromin and ethinyl estradiol, used as a prescription drug by Bryant Ranch Prepack. The patch is designed for transdermal delivery and the product has available strengths of 35 and 150 micrograms per day.*

FDA Label Image

Where To Put Patch (Zafemy Norelgestromin And Ethinyl Estradiol Transd 18)

Illustrations showing the application sites for ZAFEMY transdermal patches on a female body. The patches are shown applied on the upper arm, lower abdomen, buttocks, and upper back near the shoulder.*

FDA Label Image

Usage Illustration 1 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 19)

An illustration showing two hands demonstrating the application of a transdermal patch on the inner forearm. The image visually instructs on how to hold and place the patch, relevant for products such as ZAFEMY (Norelgestromin and Ethinyl Estradiol) transdermal patches.*

FDA Label Image

Usage Illustration 1 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 2)

An illustration showing hands applying a ZAFEMY transdermal patch to the skin. The image demonstrates the method of placement for the contraceptive patch containing Norelgestromin and Ethinyl Estradiol.*

FDA Label Image

Usage Illustration 2 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 20)

An image showing a close-up of a person holding and applying a ZAFEMY transdermal patch, demonstrating correct placement on the skin. The patch is square-shaped and appears thin and flexible.*

FDA Label Image

Usage Illustration 3 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 21)

An illustration showing hands applying a small, beige transdermal patch to a person's skin on the abdomen. The image visually demonstrates the application of a medicated skin patch.*

FDA Label Image

Usage Illustration 4 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 22)

A close-up image of a person's abdomen showing the application of a ZAFEMY transdermal patch. The patch is a small, square-shaped adhesive designed for continuous drug delivery through the skin. The person's hands are in the process of applying or adjusting the patch on the skin.*

FDA Label Image

Usage Illustration 2 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 3)

An illustration showing hands applying a ZAFEMY transdermal patch, indicating the usage method for the Norelgestromin and Ethinyl Estradiol hormonal contraceptive patch.*

FDA Label Image

Usage Illustration 3 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 4)

An illustration showing a person applying a transdermal patch to their skin. The image demonstrates the proper placement of a patch for delivering medication through the skin.*

FDA Label Image

Usage Illustration 4 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 5)

A clinical photograph shows a person's hands applying a small, square transdermal patch to their lower abdomen. The patch is thin, light-colored, and appears to be adhesive, consistent with a drug delivery device such as a contraceptive patch.*

FDA Label Image

Figure 2 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 6)

A horizontal bar chart showing the number of women with a blood clot per 10,000 woman-years for different groups: Non-CHC users, CHC users, pregnant women, and postpartum women (12 weeks only). The ranges vary from 1 to 65, with postpartum women having the highest range from 40 to 65, followed by pregnancy (5 to 20), CHC users (3 to 12), and Non-CHC users (1 to 5).*

FDA Label Image

1 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 7)

A forest plot titled 'Risk of Breast Cancer with Combined Oral Contraceptive Use,' showing effect estimates (odds ratios/relative risks) with confidence intervals for different studies from 2002 to 2017. The x-axis ranges from -1.5 to 2, with most studies clustered around 1, indicating no clear risk increase or decrease. Each study is listed by name, year, and use category (Ever or Current Use), with numeric effect estimates shown in a table to the right.*

FDA Label Image

Structural Formula (Zafemy Norelgestromin And Ethinyl Estradiol Transd 8)

Chemical structures of the active ingredients norelgestromin and ethinyl estradiol in ZAFEMY transdermal patches. The left structure shows norelgestromin and the right structure shows ethinyl estradiol, both steroid-based molecules.*

FDA Label Image

Figure 3 (Zafemy Norelgestromin And Ethinyl Estradiol Transd 9)

A line graph depicting NGMN concentration (ng/mL) over time (hours) across various cycles and weeks. Four datasets are shown: Cycle 1 Week 1, Cycle 3 Week 1, Cycle 3 Week 2, and Cycle 3 Week 3, with concentrations rising to peaks between 48 and 72 hours, then declining over time until 240 hours. The graph illustrates pharmacokinetic profiles of Norelgestromin from the ZAFEMY patch.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.